Skip to main content
Telix Pharmaceuticals Ltd logo

Telix Pharmaceuticals Ltd — Investor Relations & Filings

Ticker · TLX ISIN · AU000000TLX2 ASX Manufacturing
Open in API
Filings indexed 989 across all filing types
Latest filing 2025-02-25 Regulatory Filings
Country US United States of America
Listing ASX TLX

About Telix Pharmaceuticals Ltd

https://telixpharma.com/

Telix Pharmaceuticals is a commercial-stage biopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic radiopharmaceuticals, an approach known as 'theranostics'. The company utilizes targeted radiation to both image and treat various forms of cancer. Its extensive clinical pipeline and portfolio address key areas in oncology, including urologic (prostate and kidney), neurologic (glioma), and musculoskeletal cancers, as well as applications in bone marrow conditioning. Telix has secured global regulatory approvals for its prostate cancer imaging agent and supports its products with a robust global supply, manufacturing, and distribution network. The company is actively engaged in numerous clinical trials worldwide to expand its theranostic platform.

Recent filings

Filing Released Lang Actions
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Regulatory Filings
2025-02-25 English
Telix Announces Board Renewal 3 pages 152.7KB
Board/Management Information Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 26 February 2025. It announces changes in the company's board of directors, including retirements and new appointments, as part of a board renewal process. The content focuses on governance and leadership changes rather than financial results, audit information, or other report types. There is no indication that this is a full annual report, audit report, earnings release, or any other financial report. The document is not a proxy solicitation or voting results announcement, nor is it a regulatory filing or legal proceeding update. The primary subject is the announcement of changes in the company's board and senior management. Therefore, the most appropriate classification is Board/Management Information (MANG). The document length (9451 characters) supports that this is a substantive announcement rather than a brief notice or report publication announcement. Confidence is high given the clear focus on board changes.
2025-02-25 English
FDA accepts BLA and grants priority review for Zircaix 3 pages 156.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited regarding the FDA acceptance of a Biologics License Application (BLA) for a new imaging agent, TLX250-CDx, and its priority review status. It is a regulatory update about a product development milestone and regulatory progress, not a financial report, earnings release, or management discussion. The document is approximately 9,895 characters, which is relatively short and focused on a specific regulatory event. It does not contain financial statements, detailed financial analysis, or management commentary typical of annual or interim reports. It also does not fit categories like M&A, capital updates, or governance changes. The content is best classified as a Regulatory Filing (RNS) because it is a general regulatory announcement about FDA acceptance and priority review of a product application, which is a typical use of the RNS category as a fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2025-02-25 English
Notice of Pending Sale of Shares by Telix CEO 2 pages 141.9KB
Director's Dealing Classification · 95% confidence The document is an ASX announcement titled 'Notice of Pending Sale of Shares by Telix CEO'. It details the planned sale of shares by the CEO, including the number of shares, reasons for the sale, and lock-up arrangements. It references the company's recent annual financial results and Form 20-F filings but does not contain any financial statements or detailed financial data itself. The document is about a director's personal share transaction and insider trading disclosure. Therefore, it fits the category of Director's Dealing (DIRS). The document length (8684 characters) is sufficient to be a full announcement rather than a brief notice or report publication announcement.
2025-02-25 English
CURRENT REPORT OF FOREIGN ISSUER PURSUANT TO RULES 13A-16 AND 15D-16 AMENDMENTS
Regulatory Filings
2025-02-24 English
Telix Announces Change in Reporting Currency to USD 2 pages 133.6KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement from Telix Pharmaceuticals Limited dated 25 February 2025. It announces a change in the company's reporting currency to USD effective 1 January 2025. The text references accounting standards and future financial reports but does not contain any actual financial statements or detailed financial data. It is a corporate announcement about a change in reporting policy rather than a full financial report or detailed management discussion. The document is about a change in reporting currency and is an update to investors and the market, not a report itself. The length is 6562 characters, which is relatively short and consistent with an announcement. Therefore, this document fits best under the category of Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other specific categories.
2025-02-24 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.